Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lonza Group Ltd ( (CH:LONN) ) has provided an announcement.
Lonza Group AG reported a strong Q3 2025 performance, confirming its full-year outlook for its CDMO and CHI businesses. The company saw significant contract signings and growth in its Integrated Biologics and Advanced Synthesis segments, supported by the Vacaville acquisition. The CHI business returned to growth, aided by higher volumes in pharmaceutical capsules and a strong US manufacturing presence. Lonza expects continued robust demand and minimal impact from US trade policies, maintaining confidence in its global manufacturing capabilities.
The most recent analyst rating on (CH:LONN) stock is a Buy with a CHF606.00 price target. To see the full list of analyst forecasts on Lonza Group Ltd stock, see the CH:LONN Stock Forecast page.
More about Lonza Group Ltd
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. It operates globally with a team of over 19,000 employees, collaborating with pharma and biotech companies to develop therapies. Lonza generated sales of CHF 3.6 billion with a CORE EBITDA of CHF 1.1 billion in the first half of 2025.
Average Trading Volume: 117,800
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF37.78B
For an in-depth examination of LONN stock, go to TipRanks’ Overview page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts